Functional activity of aryl hydrocarbon receptor in human osteosarcoma cell cultures
Abstract
Osteosarcoma is the most prevalent bone malignant tumor with a high mortality rate among children and adolescents. The aryl hydrocarbon receptor (AHR) is a ligand-dependent transcription factor associated with xenobiotic detoxification and carcinogenesis. It is known that some AHR ligands are included in the composition of drugs used in cancer therapy. However there are few works devoted to the study of their effect on osteosarcoma cells. In this work, three primary cell cultures were obtained from biopsy material of malignant bone tumors of human osteosarcoma. AHR protein levels were high in all primary osteosarcoma cell cultures. The functional activity of AHR in osteosarcoma cells was estimated by induction of its target genes by known exogenous ligands: indirubin and indole-3-carbinol. The genes of Cytochrome P450 1 family were analyzed as AHR target genes: CYP1A1, CYP1A2, CYP1B1. It was shown that the aryl-hydrocarbon receptor is functionally active in all cultures, but the target genes were induced differently by ligand treatment within the same cell culture.
About the Authors
Yu. E. Vorontsova
Koltzov Institute of Developmental Biology of Russian Academy of Sciences
Russian Federation
119334, Moscow, Vavilov Street, 26
Russian Federation
119334, Moscow, Vavilov Street, 26
A. A. Akishina
Koltzov Institute of Developmental Biology of Russian Academy of Sciences
Russian Federation
119334, Moscow, Vavilov Street, 26
Russian Federation
119334, Moscow, Vavilov Street, 26
R. O. Cherezov
Koltzov Institute of Developmental Biology of Russian Academy of Sciences
Russian Federation
119334, Moscow, Vavilov Street, 26
Russian Federation
119334, Moscow, Vavilov Street, 26
O. B. Simonova
Koltzov Institute of Developmental Biology of Russian Academy of Sciences
Russian Federation
119334, Moscow, Vavilov Street, 26
Russian Federation
119334, Moscow, Vavilov Street, 26
References
1. Amankwah E.K., Conley A.P. Reed D.R. Epidemiology and therapies for metastatic sarcoma // Clin. Epidemiol. 2013. Vol. 5. P. 147–162.
2. Ritter J., Bielack S.S. Osteosarcoma // Ann. Oncol. 2010. Vol. 21. Suppl. 7. P. 320–325.
3. Hattinger C.M., Serra M. Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma // Expert Opin. Drug Metab. Toxicol. 2015. Vol. 11. N 9. P. 1449–1463.
4. Byrgazov K., Anderson C., Salzer B., Bozsaky E., Larsson R., Gullbo J., Lehner M., Lehmann F., Slipicevic A., Kager L., Fryknäs M., Taschner-Mandl S. Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide // Ther. Adv. Med. Oncol. 2020. Vol. 12: e1758835920937891.
5. Vorontsova J.E., Cherezov R.O., Kuzin B.A., Simonova O.B. Aryl-hydrocarbon receptor as a potential target for anticancer therapy // Biochem. (Mosc.), Suppl., Ser. B Biomed. Chem. 2019. Vol. 13. N 1. P. 36–54.
6. Feng S., Cao Z., Wang X. Role of aryl hydrocarbon receptor in cancer // Biochim. Biophys. Acta. 2013. Vol. 1836. N 2. P. 197–210.
7. Safe S., Jayaraman A., Chapkin R.S. Ah receptor ligands and their impacts on gut resilience: structure-activity effects // Crit. Rev. Toxicol. 2020. Vol. 50. N 6. P. 463–473.
8. Pollenz R.S., Barbour E.R. Analysis of the complex relationship between nuclear export and aryl hydrocarbon receptor-mediated gene regulation // Mol. Cell Biol. 2000. Vol. 20. N 16. P. 6095–6104.
9. Nebert D.W., Roe A.L., Dieter M.Z., Solis W.A., Yang Y., Dalton T.P. Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis // Biochem. Pharmacol. 2000. Vol. 59. N 1. P. 65–85.
10. Beischlag T.V., Luis Morales J., Hollingshead B.D., Perdew G.H. The aryl hydrocarbon receptor complex and the control of gene expression // Crit. Rev. Eukaryot. Gene Expr. 2008. Vol. 18. N 3. P. 207–250.
11. Pollenz R.S. The mechanism of AH receptor protein down-regulation (degradation) and its impact on AH receptor-mediated gene regulation // Chem. Biol. Interact. 2002. Vol. 141. N 1–2. P. 41–61.
12. Narasimhan S., Stanford Zulick E., Novikov O., Parks A.J., Schlezinger J.J., Wang Z., Laroche F., Feng H., Mulas F., Monti S., Sherr D.H. Towards resolving the proand anti-tumor effects of the aryl hydrocarbon receptor // Int. J. Mol. Sci. 2018. Vol. 19. N 5. e1388.
13. Murray I.A., Morales J.L., Flaveny C.A., Dinatale B.C., Chiaro C., Gowdahalli K., Amin S., Perdew G.H. Evidence for ligand-mediated selective modulation of aryl hydrocarbon receptor activity // Mol. Pharmacol. 2010. Vol. 77. N 2. P. 247–254.
14. Miki Y., Hata S., Ono K., Suzuki T., Ito K., Kumamoto H., Sasano H. Roles of aryl hydrocarbon receptor in aromatase-dependent cell proliferation in human osteoblasts // Int. J. Mol. Sci. 2017. Vol. 18. N 10: 2159.
15. Montazeri-Najafabady N., Dabbaghmanesh M.H., Chatrabnous N., Arabnezhad M.R. The effects of astaxanthin on proliferation and differentiation of MG-63 osteosarcoma cells via aryl hydrocarbon receptor (AhR) pathway: A comparison with AhR endogenous ligand // Nutr. Cancer. 2019. Vol. 72. N 8. P. 1400–1410.
16. Pfaffl M.W., Horgan G.W., Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in realtime PCR // Nucleic Acids Res. 2002. Vol. 30. N 9: e36.
Review
For citations:
Vorontsova Yu.E., Akishina A.A., Cherezov R.O., Simonova O.B. Functional activity of aryl hydrocarbon receptor in human osteosarcoma cell cultures. Vestnik Moskovskogo universiteta. Seriya 16. Biologiya. 2020;75(4):291-295. (In Russ.)
Views:
351
Email this article 